Monday, July 16, 2018
 
 
Company News: Page (1) of 1 - 04/10/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
PAIN DOCTOR Pain & Regenerative Medicine Offers New BioBurst Rejuv and Liveyon ReGen® Umbilical Cord Stem Cell Therapies and AmnioFix® Treatment to Promote Tissue Healing
 
(April 10, 2018)
PAIN DOCTOR Pain & Regenerative Medicine Offers New BioBurst Rejuv and Liveyon ReGen® Umbilical Cord Stem Cell Therapies and AmnioFix® Treatment to Promote Tissue Healing

The partners at PAIN DOCTOR Pain & Regenerative Medicine are pleased to bring new regenerative treatments to their patients in Arlington, Ft. Worth, Dallas and surrounding communities. BioBurst Rejuv and Liveyon ReGen® umbilical cord stem cell therapies, and AmnioFix® composite amniotic tissue membrane help promote and accelerate healing for many acute and chronic injuries. Patients who have not seen an improvement in soft tissue injuries with more traditional pain management techniques, or who are trying to delay or eliminate joint replacement, now have more options with these innovative treatments.

Platelet rich plasma (PRP) treatment and bone marrow aspirate concentrate (BMAC) can help promote healing for many patients suffering from soft tissue injuries; however, as the body ages, it becomes more difficult to achieve tissue regeneration using its own pluripotent stem cells. For patients over the age of 60, a combination of PRP and umbilical cord stem cells can help promote optimal tissue regeneration.

BioBurst Rejuv and Liveyon ReGen® umbilical cord stem cells are a rich source of growth factors including collagen, elastin and fibronectin, which all help support tissue repair and regeneration. Umbilical cord stem cells also provide anti-adhesive and anti-microbial properties that play an important role in treating soft tissue injuries. BioBurst Rejuv and Liveyon ReGen® umbilical cord stem cell treatments both meet and exceed the highest industry standards. These stem cells are received after a childbirth from a healthy donor who has been pre-screened through an extensive medical review.



AmnioFix® is a new joint arthritis treatment that enhances soft tissue healing. While AmnioFix® is not considered a regenerative therapy, this treatment contains growth factors that have similar characteristics to placental tissues. These growth factors help reduce inflammation and scar tissue formation while promoting healing at the injection site. AmnioFix® is a viable treatment option for patients attempting to delay or eliminate joint replacement surgery.

To learn if you are a candidate for BioBurst Rejuv umbilical cord stem cell therapy, Liveyon ReGen® umbilical cord stem cell therapy or AmnioFix® joint arthritis treatment, please call our office at 817-468-4343.

About PAIN DOCTOR Pain & Regenerative Medicine

Regenerative medicine physicians Dr. Andrew Cottingham, Dr. Michael Phillips and Dr. Scott Berlin provide leading edge regenerative medicine options to patients in Arlington, Ft. Worth, Dallas and surrounding Texas communities who are suffering from acute and chronic pain. Each physician on the team is double board certified in anesthesiology and pain medicine and their collective expertise includes a full range of treatment options. No matter what your stage of life, PAIN DOCTOR Pain & Regenerative Medicine delivers comprehensive, current and most importantly, compassionate medical care.

Read the full story at http://www.prweb.com/releases/umbilical-cord-stem-cell/arthritis-treatment/prweb15391145.htm.


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Personal Care Home Consultant Lynn Marting Helps Families Find the Right Facility for Aging Loved Ones
  • Mount Sinai Health System and Arena Address AI-Driven Hiring for Healthcare at Leading Industry Conference
  • Connected Health Devices: Global Market Forecast to 2023 - CAGR to Grow at 21.1%, Driven by the Increasing Adoption of IT in Healthcare
  • Global Special Purpose Needles Industry
  • Gregory J. Paul, MA Honored as a Top Executive by Strathmore's Who's Who Worldwide Publication

    Cancer
  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Global Rice Bran Oil Market Professional Survey Report, 2018 by Radiant Insights
  • RiMO Therapeutics Announces Enrollment of the First Patient in Phase 1 Study of RiMO-301 With Radiation in Advanced Tumors
  • Patient Advocate Foundation Receives Grant to Advance Cost of Care Conversations between Patients and Health Care Providers
  • CytRx Corporation to Present at the Singular Research Summer Solstice 2018 Conference
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines